Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Skeeter Bug who wrote (26024)	10/7/1998 6:34:00 AM
From: Henry Niman	Respond to of 32384

LGND could become a large cosmeceuticals player. I'm not sure why LGND has not pushed topical formulations for treating non-malignant skin problems. Rextinoids (Retin-A, Accutane, Renova, Tazarotene) was been approved for treating psoriasis, acne, and wrinkles , and it seems likely that topical Panretin and Targretin would have similar applications. Instead, LGND has focused on oral versions of Panretin and Targretin for psoriasis. Phase II has been completed for Panretin and a similar trial using Targretin is finishing up. I believe that both show efficacy, but the issue is more in the area of potential concern about side effects, which are probably less in topical versions. Perhaps they are expecting some off label use of the topical formulations, but in any event, I'm not sure that topical trials have been started. The lack of focus in this area may be related to the original joint venture with AGN. Their Tazarotene targets these markets, and therefore a second generation compound may have been placed on the back burner.